UroGen Pharma (URGN) - Price-to-Projected Revenue Ratio

urogen.com (URGN) - corporate logo

Geopolitical tensions in Israel create challenges for the stability of UroGen Pharma Ltd. (URGN) laboratories, which is confirmed by the forward P/S ratio. The current value of 5.10 describes the actual status of the metric. Risks are linked to stringent ESG standards for reagent disposal; however, the scaling of Jelmyto sales and the anticipation of an FDA verdict serve as powerful drivers for the company's capitalization growth.

urogen.com - URGN Projected Price to Revenue (period 07/04/2022 - 11/16/2026)

UroGen Pharma - analytical breakdowns and key metrics (URGN)

- market price and analyst price targets:
Summary company analysis:URGN (UroGen Pharma)
Original product of urogen.com

UroGen Pharma Ltd. (URGN) focuses on urological oncology, mitigating narrow portfolio risks by expanding the application of its gel-based drugs. The projected price-to-sales ratio digitizes this strategy, comparing current market capitalization with expected annual sales. This price action reflects how the market assesses the probability of commercial success for new developments. An increase in this metric signals a premium for business scalability, although it requires close monitoring of the competitive landscape.

Direct competitors

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Bicara Therapeutics Inc (BCAX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio personalis.com|Forward Price-to-Revenue Multiple Erasca Corp (ERAS)|Forward Price-to-Revenue Multiple DCTH (Delcath)|Market Cap to Expected Sales Ratio Y-mAbs Therapeutics, Inc.|Forward P/S Multiple AURA (Aura Biosciences Inc)|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CTOR|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple